-+ 0.00%
-+ 0.00%
-+ 0.00%

CG Oncology reports Phase 2 CORE-008 combo trial posts 92.3% complete response rate

PUBT·05/15/2026 12:03:44
Listen to the news
CG Oncology reports Phase 2 CORE-008 combo trial posts 92.3% complete response rate
  • CG Oncology reported first Phase 2 results from CORE-008 Cohort CX, with data scheduled for presentation tomorrow at Society of Urologic Oncology session during 2026 American Urological Association annual meeting.
  • Study tested intravesical cretostimogene grenadenorepvec combined with gemcitabine in high-risk non-muscle invasive bladder cancer patients previously exposed to BCG or classified as BCG-unresponsive.
  • Results showed strong early signs of tumor clearance in patients with carcinoma in situ, with disease-control outcomes holding up over initial follow-up.
  • Efficacy looked similar across concurrent versus sequential dosing schedules, supporting flexibility in how regimen could be used in practice.
  • Safety profile appeared clean in this dataset, with no severe treatment-related events reported.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CG Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150800PRIMZONEFULLFEED9720834) on May 15, 2026, and is solely responsible for the information contained therein.